NCT07213466View on ClinicalTrials.gov

Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 22, 2025

Primary Completion Date

October 22, 2027

Study Completion Date

January 1, 2028

Conditions
Bipolar I DisorderBipolar II DisorderSchizo Affective DisorderObesityWeight LossGLP - 1
Interventions
BEHAVIORAL

Group Therapy Program

a 12-week group therapy program centered around weight loss and healthy eating.

DRUG

semaglutide

Brand name: Wegovy

DRUG

Phentermine-Topiramate

Brand name: Qsymia

DRUG

naltrexone and bupropion (combination)

Brand name: Contrave

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

University of Toronto

OTHER

lead

Mayo Clinic

OTHER